Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study
Authors:
- Yuan ChengYCYuan Cheng
- Binghua LiBLBinghua Li
- Decai YuDYDecai Yu
Open Access
- 1 May 2026
- journal article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-8
Abstract
Hepatocellular carcinoma (HCC) exhibits substantial biological and metabolic heterogeneity, contributing to variable therapeutic responses in unresectable disease. Although immune checkpoint inhibitors combined with anti-angiogenic agents have improved outcomes, treatment selection remains largely empirical because validated predictive biomarkers are lacking. Recent multi-omics studies have identified fatty acid degradation (FAD)-related transcriptional signatures that classify HCC into distinct metabolic subtypes with different immune microenvironment characteristics and therapeutic vulnerabilities. Retrospective analyses suggest that F1/F2 subtypes may derive greater benefit from immune checkpoint inhibitor-based systemic therapy, whereas F3 tumours may be more responsive to transarterial chemoembolisation (TACE). However, whether FAD-based metabolic stratification can prospectively inform treatment allocation remains unknown. FAD-HCC-01 is a prospective, multicentre, open-label proof-of-concept Phase II study designed to evaluate the feasibility and preliminary clinical activity of FAD-informed treatment allocation in patients with unresectable HCC. Eligible patients with Barcelona Clinic Liver Cancer stage B or C disease and no prior systemic therapy will undergo baseline tumour transcriptomic profiling to determine FAD subtype. Patients with F1/F2 tumours will receive camrelizumab plus rivoceranib, whereas patients with F3 tumours will receive TACE combined with camrelizumab and rivoceranib. Eighty-six patients will be enrolled, with 43 in each biomarker-defined cohort. The primary endpoint is objective response rate according to RECIST version 1.1. Secondary endpoints include objective response rate by mRECIST, disease control rate, progression-free survival, overall survival, duration of response, conversion to curative treatment, and safety. Exploratory analyses will assess concordance between MRI-derived proton density fat fraction and transcriptomic FAD classification. This proof-of-concept study will prospectively assess whether FAD-based metabolic subtyping can inform treatment allocation in unresectable HCC. The results may provide early evidence supporting metabolism-informed precision therapy and the design of future biomarker-guided clinical trials.Keywords
This publication has 21 references indexed in Scilit:
- BCLC strategy for prognosis prediction and treatment recommendations: The 2026 updateJournal of Hepatology, 2025
- World Medical Association Declaration of HelsinkiJAMA, 2025
- Fat fraction quantification by MRI predicts diagnosis and prognosis of HBV-related steatohepatitic hepatocellular carcinomaEuropean Radiology, 2024
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyThe Lancet, 2023
- Hepatocellular carcinomaThe Lancet, 2022
- The hallmarks of cancer metabolism: Still emergingCell Metabolism, 2022
- Immunotherapies for hepatocellular carcinomaNature Reviews Clinical Oncology, 2021
- Hepatocellular carcinomaNature Reviews Disease Primers, 2021
- Review of precision cancer medicine: Evolution of the treatment paradigmCancer Treatment Reviews, 2020
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009